Abstract
Background: Despite new adjuvant therapy, 50% of patients with colon cancer will have recurrent disease. This study investigated the use of a radiolabeled monoclonal antibody in locating occult tumor during surgery for recurrent colorectal cancer.
Methods: Twenty-two patients with recurrent colorectal cancer underwent surgery using the radioimmunoguided surgery (RIGS) system. All patients were subjected to abdominal and chest computed tomography (CT). Before surgery, patients were injected with the CC49 monoclonal antibody (MoAb), anti-TAG antibody labeled with125I. Ten patients with elevated carcinoembryonic antigen (CEA) levels and no CT findings had a scintigraphy scan with an anti-CEA MoAb labeled with99Tc. Human antimouse antibody levels of these patients were within normal limits. Surgical exploration including liver ultrasound examination was followed by survey with a gamma-detecting probe (GDP).
Results: There was MoAb tumor localization in 100% of the patients. CT found nine tumor sites, traditional surgical exploration 30, and the GDP 51, with 44 confirmed by pathology (hematoxylin and eosin). The RIGS system found occult tumor in 10 patients (45.4%) and resulted in major changes in surgical procedure in 11 patients. In the 10 patients who had scintigraphy scans, 10 tumor sites were identified, whereas RIGS found an additional eight sites.
Conclusion: RIGS technology offers a substantial benefit for patients undergoing surgery for recurrent colorectal cancer and a better chance of finding recurrent tumor intraoperatively in patients who have elevated CEA levels with no other CT findings.
Similar content being viewed by others
References
American Cancer Society.Cancer Facts and Figures—1995. Atlanta, GA: American Cancer Society, 1995:9–10.
Steele G. Advances in the treatment of early- to late-stage colorectal cancer: 20 years of progress.Ann Surg Oncol 1995;2:77–88.
Wangensteen OH, Lewis FJ, Tongen LA. The second-look in cancer surgery: a patient with colic cancer and involved lymph nodes negative on the “sixth look.”Lancet 1951;2:303–7.
Griffen WO Jr, Humphrey L, Sosin H. The prognosis and management of recurrent abdominal malignancies.Curr Prob Surg 1969;6:32–43.
Gold P, Freedman SO. Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques.J Exp Med 1965;121:439–62.
Wanebo HJ, Rao B, Pinsky CM, et al. Preoperative carcinoembryonic antigen level as prognostic indicator in colorectal cancer.N Engl J Med 1978;299:448–51.
Minton EW, Hoehn IL, Gerber DM, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study.Cancer 1985;55:1284–90.
Doerr RJ, Abdel-Nabi H, Krag D, Mitchell E. Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study.Ann Surg 1991;214:118–24.
Martin EW, Carey LC. Second-look surgery for colorectal cancer. The second time around.Ann Surg 1991;214:321–7.
Arnold MW, Schneebaum S, Berens A, et al. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-look generation monoclonal antibody.Ann Surg 1992;216:627–32.
Bertsch DJ, Burak WE, Young DC, Arnold MW, Martin EW. Radioimmunoguided surgery system improves survival for patients with recurrent colorectal cancer.Surgery 1995;118:634–9.
Gunderson LL, Tepper JE, Dosoretz DE, et al. Patterns of failure after treatment of gastrointestinal cancer.Cancer Treat Symp 1983;2:181–97.
Machi J, Isomoto H, Kurohiji T, et al. Accuracy of intraoperative ultrasonography in diagnosing liver metastasis from colorectal cancer: evaluation with postoperative follow-up results.World J Surg 1991;15:551–7.
Hughes HS, Sugarbaker PH. Resection of the liver for metastatic solid tumors. In: Rosenberg SA, ed.Surgical Treatment of Metastatic Cancer. Philadelphia: JB Lippincott, 1987:125–64.
Sardi A, Minton JP, Nieroda C, Sickle-Santanello B, Young B, Martin EW Jr. Multiple reoperations in recurrent colorectal carcinoma an analysis of morbidity, mortality, and survival.Cancer 1988;61:1913–9.
Schneebaum S, Arnold MW, Houchens DP, et al. The significance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma.Cancer 1995;75:2809–17.
Fuhrman GM, Curley SA, Hohn DC, Roh MS. Improved survival after resection of colorectal liver metastases.Ann Surg Oncol 1995;2:537–41.
Cote RJ, Houchens DP, Hitchcock CL, et al. Intraoperative detection of occult colon cancer micrometastases using125I-radiolabeled monoclonal antibody CC49.Cancer 1996;77:613–20.
Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer; comparison with conventional imaging.Eur J Surg Oncol 1995;21:517–22.
Steele G, Zamcheck N, Wilson R, et al. Results of CEA-initiated second-look surgery for recurrent colorectal cancer.Am J Surg 1980;139:544–8.
Cady B, Stone MD, McDermott WV Jr, et al. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases.Arch Surg 1992;127:561–9.
Schneebaum S, Arnold MW, Young D, et al. Role of carcinoembryonic antigen in predicting resectability of recurrent colorectal cancer.Dis Colon Rectum 1993;36:810–15.
Martin EW, Cooperman M, Carey LC, Minton JP. Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigen.J Surg Res 1980;28:389–94.
Sardi A. Multiple operations for recurrent colorectal cancer.Semin Surg Oncol 1991;7:146–56.
Staab HJ, Anderer FA, Stumpf E, Fischer R. Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer.Am J Surg 1978;136:322–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schneebaum, S., Papo, J., Graif, M. et al. Radioimmunoguided surgery benefits for recurrent colorectal cancer. Annals of Surgical Oncology 4, 371–376 (1997). https://doi.org/10.1007/BF02305548
Issue Date:
DOI: https://doi.org/10.1007/BF02305548